155 related articles for article (PubMed ID: 26404740)
1. Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia.
Kulpa J; Skrabs C; Simanek R; Valent P; Panzer S; Lechner K; Sillaber C; Jäger U
Wien Klin Wochenschr; 2016 Apr; 128(7-8):234-7. PubMed ID: 26404740
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.
Piatek CI; Bocian H; Algaze S; Weitz IC; O'Connell C; Liebman HA
Acta Haematol; 2020; 143(3):244-249. PubMed ID: 31665725
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia.
Rattarittamrong E; Eiamprapai P; Tantiworawit A; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Hematology; 2016 Jul; 21(6):368-74. PubMed ID: 27077773
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.
Roumier M; Loustau V; Guillaud C; Languille L; Mahevas M; Khellaf M; Limal N; Noizat-Pirenne F; Godeau B; Michel M
Am J Hematol; 2014 Sep; 89(9):E150-5. PubMed ID: 24847759
[TBL] [Abstract][Full Text] [Related]
5. Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report.
Ajmi H; Mabrouk S; Hassayoun S; Regaieg H; Tfifha M; Jalel C; Skouri H; Zouari N; Abroug S
J Med Case Rep; 2017 Nov; 11(1):321. PubMed ID: 29132419
[TBL] [Abstract][Full Text] [Related]
6. [Autoimmune hemolytic anemia in children. Apropos of 14 cases].
Leverger C; Fischer A; Revillon Y; Griscelli C
Arch Fr Pediatr; 1984 Dec; 41(10):665-71. PubMed ID: 6532355
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
[TBL] [Abstract][Full Text] [Related]
8. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia.
Dussadee K; Taka O; Thedsawad A; Wanachiwanawin W
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S165-70. PubMed ID: 20364571
[TBL] [Abstract][Full Text] [Related]
10. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab.
Mahévas M; Michel M; Vingert B; Moroch J; Boutboul D; Audia S; Cagnard N; Ripa J; Menard C; Tarte K; Mégret J; Le Gallou S; Patin P; Thai L; Galicier L; Bonnotte B; Godeau B; Noizat-Pirenne F; Weill JC; Reynaud CA
J Autoimmun; 2015 Aug; 62():22-30. PubMed ID: 26112660
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
Bussone G; Ribeiro E; Dechartres A; Viallard JF; Bonnotte B; Fain O; Godeau B; Michel M
Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
[TBL] [Abstract][Full Text] [Related]
12. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
13. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias.
Panigrahi A; Clark A; Myers J; Raj A
Pediatr Blood Cancer; 2017 Feb; 64(2):287-293. PubMed ID: 27615037
[TBL] [Abstract][Full Text] [Related]
14. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Zanella A
Eur J Haematol; 2013 Dec; 91(6):546-51. PubMed ID: 24033754
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary aspergillosis and central nervous system hemorrhage as complications of autoimmune hemolytic anemia treated with corticosteroids.
Cleri DJ; Moser RL; Villota FJ; Wang Y; Husain SA; Nadeem S; Anjari T; Sajed M
South Med J; 2003 Jun; 96(6):592-5. PubMed ID: 12938787
[TBL] [Abstract][Full Text] [Related]
16. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune haemolytic anaemia: pattern of presentation and management outcome in a Nigerian population: a ten-year experience.
Salawu L; Durosinmi MA
Afr J Med Med Sci; 2002 Jun; 31(2):97-100. PubMed ID: 12518900
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Battista ML; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Fanin R; Zanella A
Blood; 2012 Apr; 119(16):3691-7. PubMed ID: 22267606
[TBL] [Abstract][Full Text] [Related]
19. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Laribi K; Bolle D; Ghnaya H; Sandu A; Besançon A; Denizon N; Truong C; Pineau-Vincent F; de Materre AB
Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026
[TBL] [Abstract][Full Text] [Related]
20. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.
Ghaly S; Costello S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; Antoniades S; Headon B; Connor S; Lawrance IC; Sparrow M; Walsh AJ; Andrews JM;
Intern Med J; 2015 Feb; 45(2):170-7. PubMed ID: 25370691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
